FSD Pharma Past Earnings Performance

Past criteria checks 0/6

FSD Pharma's earnings have been declining at an average annual rate of -5.3%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 6.8% per year.

Key information

-5.3%

Earnings growth rate

31.6%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate6.8%
Return on equity-154.1%
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

No updates

Recent updates

We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Apr 13
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Dec 17
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

Aug 25
Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

How Many FSD Pharma Inc. (CSE:HUGE) Shares Did Insiders Buy, In The Last Year?

Feb 13
How Many FSD Pharma Inc. (CSE:HUGE) Shares Did Insiders Buy, In The Last Year?

Revenue & Expenses Breakdown
Beta

How FSD Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:HUGE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-23147
30 Jun 230-29168
31 Mar 230-31198
31 Dec 220-27167
30 Sep 220-27175
30 Jun 220-25163
31 Mar 220-30195
31 Dec 210-34236
30 Sep 210-32228
30 Jun 210-392512
31 Mar 210-30209
31 Dec 200-28188
30 Sep 200-36215
30 Jun 200-35202
31 Mar 200-41240
31 Dec 190-34200
30 Sep 190-38270
30 Jun 190-25220
31 Mar 190-16180
31 Dec 180-17170
30 Sep 180-270
30 Jun 180-770
31 Mar 180-440
31 Dec 170-330

Quality Earnings: HUGE is currently unprofitable.

Growing Profit Margin: HUGE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HUGE is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare HUGE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HUGE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (100.1%).


Return on Equity

High ROE: HUGE has a negative Return on Equity (-154.12%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.